ANTX
AN2 Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.89
−1.01%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -30.1%
- EBIT
- +6.2%
- EPS
- +13.7%
- Free cash flow
- +13.6%
- Operating cash flow
- +13.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +20.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- +30.1%
- Net income
- +31.5%
- EPS
- +32.6%
- Free cash flow
- +39.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026